Which medication can increase the likelihood of successful smoking cessation by affecting mood?

Bupropion is an atypical antidepressant that is commonly used in smoking cessation due to its unique action on neurotransmitters in the brain, particularly norepinephrine and dopamine. This modulation of mood-related neurotransmitters can help manage withdrawal symptoms and cravings associated with quitting smoking. By positively influencing mood, bupropion not only assists individuals in dealing with irritability and mood fluctuations that may arise during the cessation process but also enhances the overall likelihood of maintaining abstinence from nicotine.

In contrast to bupropion, nicotine nasal spray primarily delivers nicotine to alleviate withdrawal symptoms and cravings but does not have a direct effect on mood as a secondary benefit. Varenicline also helps with cessation by targeting nicotinic receptors, reducing cravings and withdrawal symptoms, but its primary mechanism is distinct from directly enhancing mood. Amphetamines, while impacting mood and increasing energy, are not appropriate for smoking cessation as they can lead to dependence and are not designed for this therapeutic purpose. Hence, among the options, bupropion stands out for its dual role in promoting mood stability while supporting smoking cessation efforts.